Arbutus Biopharma Corporation (ABUS)

$2.73

-0.05

(-1.8%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Arbutus Biopharma Corporation

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 4.65M → 2.14M (in $), with an average decrease of 54.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -20.10M → -19.31M (in $), with an average increase of 4.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 52.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 254.5%

Performance

  • $2.69
    $2.79
    $2.73
    downward going graph

    1.47%

    Downside

    Day's Volatility :3.58%

    Upside

    2.15%

    downward going graph
  • $1.69
    $3.29
    $2.73
    downward going graph

    38.1%

    Downside

    52 Weeks Volatility :48.63%

    Upside

    17.02%

    downward going graph

Returns

PeriodArbutus Biopharma CorporationSector (Health Care)Index (Russel 2000)
3 Months
19.83%
-0.7%
0.0%
6 Months
56.18%
6.6%
0.0%
1 Year
-5.76%
3.7%
-1.5%
3 Years
-8.25%
14.0%
-21.8%

Highlights

Market Capitalization
526.1M
Book Value
$0.62
Earnings Per Share (EPS)
-0.44
PEG Ratio
0.0
Wall Street Target Price
4.4
Profit Margin
0.0%
Operating Margin TTM
-956.64%
Return On Assets TTM
-28.7%
Return On Equity TTM
-59.99%
Revenue TTM
18.1M
Revenue Per Share TTM
0.11
Quarterly Revenue Growth YOY
-65.7%
Gross Profit TTM
-45.4M
EBITDA
-76.6M
Diluted Eps TTM
-0.44
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.45
EPS Estimate Next Year
-0.53
EPS Estimate Current Quarter
-0.12
EPS Estimate Next Quarter
-0.1

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Arbutus Biopharma Corporation(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 61.17%

Current $2.73
Target $4.40

Company Financials

FY18Y/Y Change
Revenue
5.9M
↓ 44.86%
Net Income
-57.1M
↓ 32.35%
Net Profit Margin
-967.8%
↓ 179.01%
FY19Y/Y Change
Revenue
6.0M
↑ 1.88%
Net Income
-153.7M
↑ 169.22%
Net Profit Margin
-2.6K%
↓ 1589.56%
FY20Y/Y Change
Revenue
6.9M
↑ 15.02%
Net Income
-65.2M
↓ 57.58%
Net Profit Margin
-943.17%
↑ 1614.19%
FY21Y/Y Change
Revenue
11.0M
↑ 58.92%
Net Income
-77.4M
↑ 18.62%
Net Profit Margin
-703.96%
↑ 239.21%
FY22Y/Y Change
Revenue
39.0M
↑ 255.11%
Net Income
-69.5M
↓ 10.21%
Net Profit Margin
-178.01%
↑ 525.95%
FY23Y/Y Change
Revenue
18.1M
↓ 53.51%
Net Income
-72.8M
↑ 4.89%
Net Profit Margin
-401.57%
↓ 223.56%
Q3 FY22Q/Q Change
Revenue
6.0M
↓ 58.21%
Net Income
-17.3M
↑ 21.35%
Net Profit Margin
-291.05%
↓ 190.81%
Q4 FY22Q/Q Change
Revenue
6.2M
↑ 4.92%
Net Income
-22.9M
↑ 32.26%
Net Profit Margin
-366.87%
↓ 75.82%
Q1 FY23Q/Q Change
Revenue
6.7M
↑ 7.08%
Net Income
-15.5M
↓ 32.51%
Net Profit Margin
-231.24%
↑ 135.63%
Q2 FY23Q/Q Change
Revenue
4.7M
↓ 30.45%
Net Income
-17.1M
↑ 10.55%
Net Profit Margin
-367.53%
↓ 136.29%
Q3 FY23Q/Q Change
Revenue
4.7M
↑ 0.15%
Net Income
-20.1M
↑ 17.61%
Net Profit Margin
-431.6%
↓ 64.07%
Q4 FY23Q/Q Change
Revenue
2.1M
↓ 53.95%
Net Income
-19.3M
↓ 3.94%
Net Profit Margin
-900.33%
↓ 468.73%
FY18Y/Y Change
Total Assets
227.9M
↓ 3.92%
Total Liabilities
27.7M
↓ 49.36%
FY19Y/Y Change
Total Assets
105.5M
↓ 53.69%
Total Liabilities
32.8M
↑ 18.38%
FY20Y/Y Change
Total Assets
137.1M
↑ 29.89%
Total Liabilities
35.1M
↑ 7.08%
FY21Y/Y Change
Total Assets
204.5M
↑ 49.17%
Total Liabilities
35.0M
↓ 0.19%
FY22Y/Y Change
Total Assets
195.4M
↓ 4.43%
Total Liabilities
58.6M
↑ 67.11%
FY23Y/Y Change
Total Assets
144.4M
↓ 26.11%
Total Liabilities
38.4M
↓ 34.46%
Q3 FY22Q/Q Change
Total Assets
203.8M
↓ 5.58%
Total Liabilities
58.3M
↓ 7.03%
Q4 FY22Q/Q Change
Total Assets
195.4M
↓ 4.11%
Total Liabilities
58.6M
↑ 0.49%
Q1 FY23Q/Q Change
Total Assets
191.2M
↓ 2.15%
Total Liabilities
47.3M
↓ 19.22%
Q2 FY23Q/Q Change
Total Assets
176.8M
↓ 7.53%
Total Liabilities
42.1M
↓ 10.95%
Q3 FY23Q/Q Change
Total Assets
158.6M
↓ 10.28%
Total Liabilities
39.3M
↓ 6.71%
Q4 FY23Q/Q Change
Total Assets
144.4M
↓ 8.98%
Total Liabilities
38.4M
↓ 2.34%
FY18Y/Y Change
Operating Cash Flow
-67.9M
↑ 39.71%
Investing Cash Flow
-4.1M
↓ 114.83%
Financing Cash Flow
55.6M
↑ 12.78%
FY19Y/Y Change
Operating Cash Flow
-71.0M
↑ 4.57%
Investing Cash Flow
28.3M
↓ 786.65%
Financing Cash Flow
37.5M
↓ 32.63%
FY20Y/Y Change
Operating Cash Flow
-51.4M
↓ 27.55%
Investing Cash Flow
-14.9M
↓ 152.61%
Financing Cash Flow
86.7M
↑ 131.59%
FY21Y/Y Change
Operating Cash Flow
-67.5M
↑ 31.28%
Investing Cash Flow
-12.7M
↓ 14.96%
Financing Cash Flow
137.2M
↑ 58.2%
FY22Y/Y Change
Operating Cash Flow
-35.4M
↓ 47.65%
Investing Cash Flow
-74.9M
↑ 491.12%
Financing Cash Flow
31.8M
↓ 76.82%
Q3 FY22Q/Q Change
Operating Cash Flow
-18.7M
↓ 7.89%
Investing Cash Flow
-13.7M
↓ 0.67%
Financing Cash Flow
9.1M
↑ 7981.42%
Q4 FY22Q/Q Change
Operating Cash Flow
-17.0M
↓ 9.11%
Investing Cash Flow
12.7M
↓ 192.31%
Financing Cash Flow
11.1M
↑ 21.38%
Q1 FY23Q/Q Change
Operating Cash Flow
-27.3M
↑ 60.69%
Investing Cash Flow
16.7M
↑ 31.51%
Financing Cash Flow
20.4M
↑ 84.2%
Q2 FY23Q/Q Change
Operating Cash Flow
-19.6M
↓ 28.36%
Investing Cash Flow
1.4M
↓ 91.36%
Financing Cash Flow
4.7M
↓ 76.77%

Technicals Summary

Sell

Neutral

Buy

Arbutus Biopharma Corporation is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
9.45%
56.18%
-5.76%
-8.25%
-12.58%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
NA
NA
0.0
-0.45
-0.6
-0.29
NA
0.62
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
Buy
$526.1M
-12.58%
NA
0.0%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%

Institutional Holdings

  • Whitefort Capital Management, LP.

    7.77%

  • BlackRock Inc

    6.12%

  • Two Seas Capital LP

    5.32%

  • Morgan Stanley - Brokerage Accounts

    4.11%

  • Vanguard Group Inc

    3.53%

  • Woodline Partners LP

    2.78%

Corporate Announcements

  • Arbutus Biopharma Corporation Earnings

    Arbutus Biopharma Corporation’s price-to-earnings ratio stands at None

    Read More

Company Information

arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the hbv treatment landscape and cure hepatitis b virus disease. in addition to our hbv assets, we are developing a pipeline of programs that leverage our expertise in rna interference (rnai) therapeutics and our lipid nanoparticle (lnp) technology.

Organization
Arbutus Biopharma Corporation
Employees
73
CEO
Mr. Michael J. McElhaugh
Industry
Health Technology

Discover More

FAQs